全文获取类型
收费全文 | 13692篇 |
免费 | 1178篇 |
国内免费 | 47篇 |
专业分类
耳鼻咽喉 | 78篇 |
儿科学 | 559篇 |
妇产科学 | 352篇 |
基础医学 | 1605篇 |
口腔科学 | 337篇 |
临床医学 | 1447篇 |
内科学 | 3407篇 |
皮肤病学 | 273篇 |
神经病学 | 1303篇 |
特种医学 | 458篇 |
外国民族医学 | 8篇 |
外科学 | 1936篇 |
综合类 | 231篇 |
一般理论 | 1篇 |
预防医学 | 1025篇 |
眼科学 | 291篇 |
药学 | 891篇 |
中国医学 | 3篇 |
肿瘤学 | 712篇 |
出版年
2021年 | 174篇 |
2020年 | 110篇 |
2019年 | 213篇 |
2018年 | 230篇 |
2017年 | 192篇 |
2016年 | 178篇 |
2015年 | 209篇 |
2014年 | 304篇 |
2013年 | 410篇 |
2012年 | 632篇 |
2011年 | 654篇 |
2010年 | 335篇 |
2009年 | 300篇 |
2008年 | 544篇 |
2007年 | 602篇 |
2006年 | 605篇 |
2005年 | 577篇 |
2004年 | 601篇 |
2003年 | 552篇 |
2002年 | 507篇 |
2001年 | 453篇 |
2000年 | 395篇 |
1999年 | 406篇 |
1998年 | 111篇 |
1997年 | 102篇 |
1996年 | 104篇 |
1994年 | 121篇 |
1993年 | 97篇 |
1992年 | 340篇 |
1991年 | 315篇 |
1990年 | 316篇 |
1989年 | 308篇 |
1988年 | 246篇 |
1987年 | 271篇 |
1986年 | 253篇 |
1985年 | 263篇 |
1984年 | 194篇 |
1983年 | 158篇 |
1982年 | 103篇 |
1979年 | 222篇 |
1978年 | 157篇 |
1977年 | 144篇 |
1976年 | 113篇 |
1975年 | 145篇 |
1974年 | 167篇 |
1973年 | 142篇 |
1972年 | 154篇 |
1971年 | 119篇 |
1970年 | 116篇 |
1969年 | 106篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
S. Liu A. E. Patanwala J. M. Naylor N. Levy R. Knaggs J. A. Stevens B. Bugeja D. Begley K. E. Khor E. Lau R. Allen S. Adie J. Penm 《Anaesthesia》2023,78(10):1237-1248
Modified-release opioids are often prescribed for the management of moderate to severe acute pain following total hip and knee arthroplasty, despite recommendations against their use due to increasing concerns regarding harm. The primary objective of this multicentre study was to examine the impact of modified-release opioid use on the incidence of opioid-related adverse events compared with immediate-release opioid use, among adult inpatients following total hip or knee arthroplasty. Data for total hip and knee arthroplasty inpatients receiving an opioid analgesic for postoperative analgesia during hospitalisation were collected from electronic medical records of three tertiary metropolitan hospitals in Australia. The primary outcome was the incidence of opioid-related adverse events during hospital admission. Patients who received modified with or without immediate-release opioids were matched to those receiving immediate-release opioids only (1:1) using nearest neighbour propensity score matching with patient and clinical characteristics as covariates. This included total opioid dose received. In the matched cohorts, patients given modified-release opioids (n = 347) experienced a higher incidence of opioid-related adverse events overall, compared with those given immediate-release opioids only (20.5%, 71/347 vs. 12.7%, 44/347; difference in proportions 7.8% [95%CI 2.3–13.3%]). Modified-release opioid use was associated with an increased risk of harm when used for acute pain during hospitalisation after total hip or knee arthroplasty. 相似文献
2.
Joseph B. Miller Sean Calo Brian Reed Richard Thompson Bashar Nahab Evan Wu Kaleem Chaudhry Phillip Levy 《The American journal of emergency medicine》2019,37(6):1073-1077
Study objectiveIn the Emergency Department (ED) setting, clinicians commonly treat severely elevated blood pressure (BP) despite the absence of evidence supporting this practice. We sought to determine if this rapid reduction of severely elevated BP in the ED has negative cerebrovascular effects.MethodsThis was a prospective quasi-experimental study occurring in an academic emergency department. The study was inclusive of patients with a systolic BP (SBP) > 180 mm Hg for whom the treating clinicians ordered intensive BP lowering with intravenous or short-acting oral agents. We excluded patients with clinical evidence of hypertensive emergency. We assessed cerebrovascular effects with measurements of middle cerebral artery flow velocities and any clinical neurological deterioration.ResultsThere were 39 patients, predominantly African American (90%) and male (67%) and with a mean age of 50 years. The mean pre-treatment SBP was 210 ± 26 mm Hg. The mean change in SBP was ?38 mm Hg (95% CI ?49 to ?27) mm Hg. The average change in cerebral mean flow velocity was ?5 (95% CI ?7 to ?2) cm/s, representing a ?9% (95% CI ?14% to ?4%) change. Two patients (5.1%, 95% CI 0.52–16.9%) had an adverse neurological event.ConclusionWhile this small cohort did not find an overall substantial change in cerebral blood flow, it demonstrated adverse cerebrovascular effects from rapid BP reduction in the emergency setting. 相似文献
3.
Joseph F. Levy Rahul Khairnar Alexander V. Louie Timothy N. Showalter C. Daniel Mullins Mark V. Mishra 《Practical radiation oncology》2019,9(2):e172-e179
Purpose
A hydrogel rectal spacer (HRS) is a medical device that is approved by the U.S. Food and Drug Administration to increase the separation between the prostate and rectum. We conducted a cost-effectiveness analysis of HRS use for reduction in radiation therapy (RT) toxicities in patients with prostate cancer (PC) undergoing external beam RT (EBRT).Methods and Materials
A multistate Markov model was constructed from the U.S. payer perspective to examine the cost-effectiveness of HRS in men with localized PC receiving EBRT (EBRT alone vs EBRT + HRS). The subgroups analyzed included site of HRS placement (hospital outpatient, physician office, ambulatory surgery center) and proportion of patients with good baseline erectile function (EF). Data on EF, gastrointestinal and genitourinary toxicities incidence, and potential risks associated with HRS implantation were obtained from a recently published randomized clinical trial. Health utilities and costs were derived from the literature and the 2018 Physician Fee Schedule and were discounted 3% annually. Quality-adjusted life years (QALYs) and costs were modeled for a 5-year period from receipt of RT. Probabilistic sensitivity analysis and value-based threshold analyses were conducted.Results
The per-patient 5-year incremental cost for spacers administered in a hospital outpatient setting was $3578, and the incremental effectiveness was 0.0371 QALYs. The incremental cost-effectiveness ratio was $96,440/QALY for patients with PC undergoing HRS insertion in a hospital and $39,286/QALY for patients undergoing HRS insertion in an ambulatory facility. For men with good baseline EF, the incremental cost-effectiveness ratio was $35,548/QALY and $9627/QALY in hospital outpatient and ambulatory facility settings, respectively.Conclusions
Based on the current Medicare Physician Fee Schedule, HRS is cost-effective at a willingness to pay threshold of $100,000. These results contain substantial uncertainty, suggesting more evidence is needed to refine future decision-making. 相似文献4.
5.
6.
7.
Raffaella Marcheselli Alessia Bari Tamar Tadmor Luigi Marcheselli Maria Christina Cox Robel Papotti Angela Ferrari Luca Baldini Paolo Gobbi Ilana Levy Giuseppe Pugliese Massimo Federico Aaron Polliack Samantha Pozzi Stefano Sacchi 《Hematological oncology》2020,38(4):439-445
The main purpose of this study was to assess whether it is possible to improve the prognostic impact of international prognostic index (IPI) score by combining it with peripheral blood counts. Thus, we evaluated the prognostic power of lymphocyte, neutrophil, and monocyte counts in 520 patients with diffuse large B cell lymphoma treated with R-CHOP, confirming that these parameters have a strong impact on overall survival (OS). Using revised IPI (R-IPI), 44% of patients were categorized as poor-risk and showed an OS at 5 years of 46%. As OS at 5 years of the 520 patients is 67%, it is clearly evident that R-IPI tends to overestimate the proportion of patients with poor prognosis. Accordingly, in an attempt to improve the discriminating power of R-IPI, we evaluated and compared three different scores by combining the neutrophil lymphocyte ratio (NLR) and absolute monocyte count (AMC) with the following values: (a) IPI score 3-5, (b) age > 60 years and performance status, (c) age ≥ 65 years and LDH > ULN. The three indexes studied, had a similar 5 years OS for the high-risk group (46%-52%), but the proportion of patients classified as poor-risk were 37%, 20%, and 32%, respectively, which are lower than 44% identified with R-IPI. Thus, while R-IPI overestimates the number of high-risk patients, after applying our models, it is possible to recognize patients who are truly at high-risk. Of the three scores, the most accurate appears to be that based on NLR, AMC, LDH > ULN and age ≥ 65 years, which identifies 32% of high-risk patients, correlating well with what is seen in clinical practice. 相似文献
8.
9.
Jérôme Le Pavec Séverine Feuillet Olaf Mercier Pauline Pradère Gaëlle Dauriat Adrian Crutu Valentina Florea Laurent Savale Marilyne Levy Florent Laverdure François Stephan Dominique Fabre Mitilian Delphine David Boulate Sacha Mussot Sébastien Hascoët Damien Bonnet Marc Humbert Elie Fadel 《The Journal of heart and lung transplantation》2021,40(7):652-661
10.